Local GPs commit $71m to China biotech player
EOC Pharma, a Chinese biotech developer focused on cancer treatments, has closed a RMB500 million ($71 million) Series C round raised from a group of local private equity investors.
TF Capital, Yingke Private Equity, Hanne Capital, and Everest Venture Capital joined the round, according to a statement, as did clinical trials specialist Tigermed. It follows a $32 million Series B in...
More on Greater China
Latest News
China’s largest co-working player Ucommune files for US IPO
Ucommune, China’s largest co-working space player which is considered the local equivalent to troubled US operator WeWork, has filed for a US IPO.
Chinese drone maker EHang raises $40m in US IPO
Chinese drone manufacturer EHang traded flat on its NASDAQ debut following a $40 million IPO that priced at the bottom end of the indicative range.
Tiger Global leads round for Indian invoice discounting platform
Tiger Global Management has led a $26 million Series B round for Indian B2B financing platform provider KredX.
New Zealand impact fund backs sustainable packaging player
New Zealand’s Impact Enterprise Fund (IEF) has confirmed an investment in local sustainable packaging supplier Grounded.